CARDIOVASCULAR JOURNAL OF AFRICA • Volume 34, No 3, July/August 2023 AFRICA 163 Hypertension 2015; 66(6): 1108–1115. 13. Tirosh A, Afek A, Rudich A, Percik R, Gordon B, Ayalon N, et al. Progression of normotensive adolescents to hypertensive adults: a study of 26,980 teenagers. Hypertension 2010; 56(2): 203–209. 14. Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment – a position paper of the The Obesity Society and The American Society of Hypertension. Obesity 2013; 21(1): 8–24. 15. Bogaert YE, Linas S. The role of obesity in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2009; 5(2): 101–111. 16. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 2001; 37; 1199–1208. 17. Konno S, Hozawa A, Miura Y, Ito S, Munakata M. High-normal diastolic blood pressure is a risk for development of microalbuminuria in the general population: the Watari study. J Hypertens 2013; 31(4): 798–804. 18. Munakata M, Konno S, Ohshima M, Ikeda T, Miura Y, Ito S. Highnormal blood pressure is associated with microalbuminuria in the general population: the Watari study. Hypertens Res 2011; 34(10): 1135–1140. 19. Kramer H, Colangelo L, Lewis CE, Jacobs DRJ, Pletcher M, BibbinsDomingo K, et al. Cumulative exposure to systolic blood pressure during young adulthood through midlife and the urine albumin-to-creatinine ratio at midlife. Am J Hypertens 2017; 30(5): 502–509. 20. Zheng W, Mu J, Chu C, Hu J, Yan Y, Ma Q, et al. Association of blood pressure trajectories in early life with subclinical renal damage in middle age. J Am Soc Nephrol 2018; 29(12): 2835–2846. 21. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystalindependent mechanism. Hypertension 2001; 38(5): 1101–1106. 22. Sánchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaría J, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002; 283(5): F1105–1110. 23. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res 2011; 63(1): 102–110. 24. Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One 2014; 9(12): e114259. 25. Nishio S, Maruyama Y, Sugano N, Hosoya T, Yokoo T, Kuriyama S. Gender interaction of uric acid in the development of hypertension. Clin Exp Hypertens 2018; 40(5): 446–451. 26. Halperin Kuhns VL, Woodward OM. Sex differences in urate handling. Int J Mol Sci 2020; 21(12): 4269. 27. Stuart JJ, Tanz LJ, Missmer SA, Rimm EB, Spiegelman D, James-Todd TM, et al. Hypertensive disorders of pregnancy and maternal cardiovascular disease risk factor development: an observational cohort study. Ann Intern Med 2018; 169(4): 224–232. 28. Tooher J, Thornton C, Makris A, Ogle R, Korda A, Hennessy A. All Hypertensive Disorders Of Pregnancy Increase The Risk Of Future Cardiovascular Disease. Hypertension 2017; 70(4): 798–803. 29. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. Br Med J 2003; 326(7394): 845. 30. Bellamy L, Casas J-P, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. Br Med J 2007; 335(7627): 974. 31. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008; 156(5): 918–930. 32. Rosenthal T, Oparil S. Hypertension in women. J Hum Hypertens 2000; 14(10–11): 691–704. 33. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res 2002; 53(3): 688–708. 34. Harvey PJ, Molloy D, Upton J, Wing LM. Dose response effect of cyclical medroxyprogesterone on blood pressure in postmenopausal women. J Hum Hypertens 2001; 15(5): 313–321. 35. Oelkers W, Schöneshöfer M, Blümel A. Effects of progesterone and four synthetic progestagens on sodium balance and the renin–aldosterone system in man. J Clin Endocrinol Metab 1974; 39(5): 882–890. 36. Zerihun MF, Malik T, Ferede YM, Bekele T, Yeshaw Y. Changes in body weight and blood pressure among women using Depo-Provera injection in Northwest Ethiopia. BMC Res Notes 2019; 12(1): 512. Injection could replace drugs for high BP – British trial A breakthrough may be on the horizon for millions of people suffering from high blood pressure, the leading cause of heart attacks and strokes, in the form of a six-monthly injection instead of daily medication for the condition. Known as zilebesiran, the jab targets a key hormone produced by the liver, reports The Independent. The injection, produced by US-based Alnylan Pharmaceuticals, has recently undergone trials in Britain, during which experts at Queen Mary University of London recruited 107 patients with hypertension, of whom 80 were given a shot of zilebesiran under their skin and 32 received a placebo with no active ingredients. Five of the 32 patients who were on the placebo were later given zilebesiran. Initial analysis showed that volunteers on zilebesiran experienced a significant drop in systolic blood pressure that lasted up to six months. Systolic blood pressure was lowered by more than 10 mmHg on at least a 200-mg dose and by 20 mmHg at the highest of 800 mg. The drop can take a patient’s high blood pressure into a safer range. Despite high blood pressure being difficult to treat due to its fluctuations across a day, zilebesiran resulted in a consistent drop over 24 hours. The medication prevents the production of angiotensin, a hormone that narrows blood vessels and causes blood pressure to rise, said the researchers in their article, which was reported in the New England Journal of Medicine. ‘Overall, these preliminary data… support the potential for further study of quarterly or twice-yearly administration of zilebesiran as a treatment for patients with hypertension.’ Professor David Webb, who led the trial in Edinburgh, added: ‘This is a potentially major development in hypertension. There has not been a new class of drug licensed for the treatment of high blood pressure in 17 years. This novel approach leads to a substantial reduction in blood pressure, both by day and night, that lasts for around six months after a single injection.’ Source: New England Journal of Medicine 23 July 2023
RkJQdWJsaXNoZXIy NDIzNzc=